BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Palucci I, Battah B, Salustri A, De Maio F, Petrone L, Ciccosanti F, Sali M, Bondet V, Duffy D, Fimia GM, Goletti D, Delogu G. IP-10 contributes to the inhibition of mycobacterial growth in an ex vivo whole blood assay. Int J Med Microbiol 2019;309:299-306. [PMID: 31147175 DOI: 10.1016/j.ijmm.2019.05.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Sun H, Fan J, Shang X, Tuohetaerbaike B, Li Y, Lv J, Wang Y, Wang L, Wang J, Ma X. Study on the relationship between CXCR3 and its ligands and tubal tuberculosis. Life Sci 2021;272:119047. [PMID: 33454369 DOI: 10.1016/j.lfs.2021.119047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Sivakumaran D, Jenum S, Ritz C, Vaz M, Doherty TM, Grewal HMS. Improving Assignments for Therapeutic and Prophylactic Treatment Within TB Households. A Potential for Immuno-Diagnosis? Front Immunol 2022;13:801616. [DOI: 10.3389/fimmu.2022.801616] [Reference Citation Analysis]
3 Rambaran S, Naidoo K, Lewis L, Hassan-Moosa R, Govender D, Samsunder N, Scriba TJ, Padayatchi N, Sivro A. Effect of Inflammatory Cytokines/Chemokines on Pulmonary Tuberculosis Culture Conversion and Disease Severity in HIV-Infected and -Uninfected Individuals From South Africa. Front Immunol 2021;12:641065. [PMID: 33868272 DOI: 10.3389/fimmu.2021.641065] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Shang X, Wang L, Liu Y, Liu X, Lv J, Zhou X, Wang H, Nazierhan S, Wang J, Ma X. Diagnostic value of CXCR3 and its ligands in spinal tuberculosis. Exp Ther Med 2021;21:73. [PMID: 33365073 DOI: 10.3892/etm.2020.9505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Battah B, Chemi G, Butini S, Campiani G, Brogi S, Delogu G, Gemma S. A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles. Molecules 2019;24:E4373. [PMID: 31795400 DOI: 10.3390/molecules24234373] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
6 Suzukawa M, Takeda K, Akashi S, Asari I, Kawashima M, Ohshima N, Inoue E, Sato R, Shimada M, Suzuki J, Yamane A, Tamura A, Ohta K, Tohma S, Teruya K, Nagai H. Evaluation of cytokine levels using QuantiFERON-TB Gold Plus in patients with active tuberculosis. J Infect 2020;80:547-53. [PMID: 32092390 DOI: 10.1016/j.jinf.2020.02.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Smyth R, Berton S, Rajabalee N, Chan T, Sun J. Protein Kinase R Restricts the Intracellular Survival of Mycobacterium tuberculosis by Promoting Selective Autophagy. Front Microbiol 2020;11:613963. [PMID: 33552025 DOI: 10.3389/fmicb.2020.613963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Delemarre EM, van Hoorn L, Bossink AWJ, Drylewicz J, Joosten SA, Ottenhoff THM, Akkerman OW, Goletti D, Petruccioli E, Navarra A, van den Broek BTA, Paardekooper SPA, van Haeften I, Koenderman L, Lammers JJ, Thijsen SFT, Hofland RW, Nierkens S. Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and Adenosine Deaminase Activity Distinguishes Active From Remotely Acquired Latent Tuberculosis. Front Immunol 2021;12:725447. [PMID: 34691031 DOI: 10.3389/fimmu.2021.725447] [Reference Citation Analysis]